



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:59
Last Report Issued 05/13/2019 08:05

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1440B-POS
Patient ID 1440B-POS
Chain 18001895
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 18001895
Received 11/21/2018 08:53

Sample ID 18001895-001
Matrix Blood
Patient Name 1440B-POS
Patient ID 1440B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1440B Dapsone and Metabolite, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Dapsone	50	mcg/mL	0.10	
Synonym(s): Aczone®				

Steady-state plasma concentrations from patients on 200 mg daily antileprotic therapy: 0.1 - 7.0 mcg/mL (mean = 2.3 mcg/mL). The blood to plasma ratio is approximately 1.0.

Monoacetyldapsone	50	mcg/mL	0.10	
Synonym(s): Dapsone Metabolite				

Monoacetyldapsone is an active metabolite of dapsone with antibacterial activity.

Monoacetyldapsone to Dapsone Ratio	1.0			
------------------------------------	-----	--	--	--

Monoacetyldapsone to Dapsone Ratio (for acetylation phenotyping purposes):
Slow acetylator: <0.35
Rapid acetylator: >0.35

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.